Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gamida Cell Ltd GMDAQ

Healthcare Biotechnology
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and... see more

Recent & Breaking News (OTCPK:GMDAQ)

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022

Business Wire May 5, 2022

Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast

Business Wire May 3, 2022

Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Business Wire April 27, 2022

Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201

Business Wire April 26, 2022

Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Business Wire April 25, 2022

Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Business Wire April 25, 2022

Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference

Business Wire April 7, 2022

Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

Business Wire March 15, 2022

Gamida Cell to Present Corporate Highlights at the Oppenheimer 32nd Annual Healthcare Conference

Business Wire March 10, 2022

Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results and Webcast

Business Wire March 8, 2022

Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel

Business Wire February 9, 2022

Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors

Business Wire January 31, 2022

Gamida Cell Provides Key Program Updates and 2022 Financial Guidance

Business Wire January 31, 2022

Gamida Cell Provides Update on Omidubicel BLA Submission

Business Wire January 19, 2022

Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Business Wire January 7, 2022

Gamida Cell Presents Two-Year Survival Data for GDA-201 and Resource Utilization Analysis for Omidubicel at 63rd ASH Annual Meeting

Business Wire December 13, 2021

Gamida Cell Presents New Omidubicel Data at 63rd ASH Annual Meeting

Business Wire December 11, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Gamida Cell Ltd. - GMDA

Newsfile November 28, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Gamida Cell Ltd. - GMDA

PR Newswire November 25, 2021

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

Business Wire November 16, 2021